Secondary analysis findings from the EMPACT-MI trial highlight empagliflozin's significant cardiovascular and kidney benefits when initiated soon after an acute myocardial infarction.

In elderly patients 65 years of age or older with heart failure with reduced ejection fraction (HFrEF), regular use of sodium ...

SGLT2 inhibitors have become a major drug used to treat diabetes, heart failure, and chronic kidney disease. However, there have been questions as to whether it is safe to use these drugs in ...

With studies showing potential for SGLT2 inhibitors in heart failure, a study of HCP online conversations reveals cardiologists are still cautious.

In addition newer drugs like SGLT2 inhibitors, Angiotensin receptor neprisilyn inhibitors ,beta, blockers ,mineralocorticoid ...

Investigators examined the comparative effectiveness of SGLT2 inhibitors and GLP-1 receptor agonists in a real-world setting.

SGLT2 inhibitors and GLP-1 receptor agonists lower cardiovascular risk in type 2 diabetes, but a recent review suggests that ...

SGLT-2 inhibitors market to hit $32.16B by 2033, fueled by rising diabetes, CKD & heart failure cases; USA & Japan drive regional growth. The SGLT-2 inhibitors market will grow from US$ 17.95B in ...

For patients with acute MI at increased risk for HF, empagliflozin showed cardiorenal benefits and was safe to initiate early ...

With studies showing potential for SGLT2 inhibitors in heart failure, a study of HCP online conversations reveals cardiologists are still cautious.

Even in heart attack patients with poor kidney function, researchers found SGLT2 inhibitors reduced heart failure complications.